drugset
drugset / Trial / NCT02534038

Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition

NCT02534038 ↗

Phase 2 Terminated 1 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

Treatment of disinhibition syndrome in participants with Neurodegenerative Disorder.

Timeline

Start
2015-12-01
Primary completion
2017-10-03
Completion
2017-10-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator AVP-786 Unknown — —

Indications

impulse control disorder